Cigna's pharmacy benefits company, Evernorth, reached pricing deals with Eli Lilly and Novo Nordisk to reduce expenses and provide wider employer access to GLP-1 weight-loss treatments Wegovy and ...

As of July 1, CVS Caremark — one of the biggest pharmacy benefit managers in the U.S. — dropped Zepbound (tirzepatide) from its preferred drug list, replacing it with Wegovy (semaglutide).

As of July 1, CVS Caremark — one of the biggest pharmacy benefit managers in the U.S. — dropped Zepbound (tirzepatide) from its preferred drug list, replacing it with Wegovy (semaglutide).

Zepbound and Wegovy come from the same class of GLP-1 drugs and deliver significant weight loss through a once-weekly injection. But the two medications have different main active ingredients.

The 50-year-old is now on Novo Nordisk ’s Wegovy, but worries because it is less effective. Studies have shown Wegovy helps people lose less weight, on average, than Zepbound.

The company hopes the new discount, which caps monthly out-of-pocket costs at $200 for Wegovy and Zepbound, will convince more employers to offer coverage of the drugs.

The Associated Press Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per ...

The drugs are still in high demand Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity.

Zepbound and Wegovy are prescription drugs used for weight loss and weight management. Compare their uses, cost, effectiveness, side effects, and more.

Your Wegovy May Pay for Itself The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly. In a head-to-head comparison of the two GLP-1 drugs ...